Aquestive Therapeutics, Inc.
——
Mentions · last 7 days
0
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $AQST, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $AQST.
Drug Manufacturers - Specialty & Generic
Biosimilar launches are compressing margins on branded specialty drugs; the opportunity is on the generic/biosimilar side where volume gains offset price erosion. Rare disease and oncology are the premium pockets where pricing power remains intact.
What this means for $AQST
Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.
Top industry ETF
$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+47.0%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-7.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-45.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-97.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-7.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
11.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
244%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
67.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
-1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.18$-0.10-71.4%
Q1 2026May 13, 2026$-0.07$-0.14+50.0%
Q4 2025Mar 4, 2026$-0.26$-0.13-100.0%
Q3 2025Nov 5, 2025$-0.14$-0.11-27.3%
Next earningsWed, Nov 4·consensus EPS $-0.11
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$13.8M+38.1%70.9%-59.5%$-0.18$-9.7M
Q1 FY26$14.4M+65.7%76.0%-29.1%$-0.07$-14.9M
Q4 FY25$13.0M+9.7%55.2%-222%$-0.26$-8.6M
Q3 FY25$12.8M-5.4%64.8%-89.6%$-0.14$-12.9M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$49.9M$48.6M – $51.3M-$0.49-$0.58 – -$0.446
FY27$67.8M$63.2M – $73.3M-$0.50-$0.58 – -$0.427
FY28$106.7M$97.0M – $124.3M-$0.37-$0.55 – -$0.255
FY29$187.8M$168.1M – $235.7M-$0.02-$0.02 – -$0.022
FY30$322.7M$288.8M – $404.9M$0.52$0.44 – $0.692
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.45%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+18.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+12.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 114.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.435-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KPress release / Reg FDAug 118-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary
8-KPress release / Reg FDAug 108-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary
8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
8-KAgreement terminatedMay 138-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.02: Earnings release · Item 2.03: Material debt obligation · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDMar 308-K — Item 7.01: Press release / Reg FD
8-KOfficer or director changeMar 208-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 11 other (2 10-Qs · 2 proxys · 1 13G · 1 EFFECT) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
AWM Investment Company Inc. Takes $1.98 Million Position in Aquestive Therapeutics, Inc. $AQSTAquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call TranscriptAquestive Therapeutics Q2 Earnings Call HighlightsAquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue EstimatesAquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
More in Drug Manufacturers - Specialty & Generic
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 2 · last 7 days